Last reviewed · How we verify
NCT03910400: EARLYmyoQFR-II
Early Assessment of QFR in STEMI-II
NA trial testing Computation of quantitative flow ratio in ST Segment Elevation Myocardial Infarction in 200 participants. Status unknown.
1 January 2021
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 1 February 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Computation of quantitative flow ratio
Conditions studied
- ST Segment Elevation Myocardial Infarction — all drugs for ST Segment Elevation Myocardial Infarction →
Sponsor
RenJi Hospital
Who can join
Eligibility, any sex, with ST Segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study intends to provide new data on whether the noval method using quantitative flow ratio could assess microvascular dysfunction based on the previous study EARLY-MYO-QFR-I.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03910400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Computation of quantitative flow ratio
Trials testing the same drug.
- NCT04220736 — Early Prediction of QFR in STEMI-Pharmaco-invasice · unknown
- NCT03780335 — Early Prediction of QFR in STEMI-I · completed
Other recruiting trials for ST Segment Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT03787745 — Ischemic Postconditioning in STEMI Patients Treated With Primary PCI · NA · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03910400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 10 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03910400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing